Trial · NCT07898839
FEAST and HOPE: Redox PSC Pilot Study
NCT07898839, Phase 2, Not yet recruiting, Brigham and Women's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. FEAST and HOPE: Redox PSC Pilot Study. Trials, record NCT07898839. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898839
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- FEAST and HOPE: Redox PSC Pilot Study
- NCT number
- NCT07898839
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 15 participants, estimated
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Primary Sclerosing Cholangitis (PSC)
- Interventions
- N-Acetyl Cysteine (NAC), Alpha-Lipoic Acid (ALA), Nicotinamide Riboside (NR), Metformin Hydrochloride Extended-Release Tablets, Study Diet
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Serum Alkaline Phosphatase (ALP) From Baseline to Week 16 | Baseline (Week 0) and Week 16 | Serum ALP (U/L) will be measured at Baseline and Week 16. Change will be calculated as the Week 16 value minus the Baseline value. ALP is a marker of cholestatic liver injury commonly elevated in primary sclerosing cholangitis (PSC). |
| Primary | Percentage of Participants With ≥50% Reduction in Serum ALP at Week 16 | Baseline (Week 0) and Week 16 | ALP response is defined as a reduction of 50% or more from baseline at Week 16. Reported as the proportion of participants achieving response, with 95% confidence interval. |
| Secondary | Change in Liver Biochemistry From Baseline to Week 16 | Baseline (Week 0) and Week 16 | Change in serum gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin from Baseline to Week 16. |
| Secondary | Change in Pro-peptide of Type III Collagen (PRO-C3) From Baseline to Week 16 | Baseline (Week 0) and Week 16 | Serum PRO-C3 (ng/mL), a biomarker of liver fibrogenesis. Change from baseline to Week 16 is reported as absolute and percent change from baseline. |
| Secondary | Change in Enhanced Liver Fibrosis (ELF) Score From Baseline to Week 16 | Baseline (Week 0) and Week 16 | The ELF score is a composite serum fibrosis score calculated from hyaluronic acid, amino-terminal propeptide of type III procollagen (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1). Change from baseline to Week 16 is reported as absolute and percent change from baseline. |
| Secondary | Change in LMR Inflammatory Panel Markers From Baseline to Weeks 8 and 16 | Baseline (Week 0), Week 8, and Week 16 | Serum inflammatory and metabolic markers measured using the LMR Inflammatory Panel. Change from baseline to Week 8 and to Week 16 is reported. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898839
GET https://conductscience.org/api/trials/v1/NCT07898839/registered